名臣健康(002919) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥218,438,464.02, representing a 27.29% increase compared to the same period last year[5] - The net profit attributable to shareholders was -¥45,526,989.51, a decrease of 305.80% year-on-year[5] - The net cash flow from operating activities was -¥91,884,294.74, a significant decline of 2,529.31% compared to the previous year[5] - The company's basic earnings per share were -¥0.27, down 307.69% year-on-year[5] - The company reported a net operating loss of RMB 29,404,454.99, a significant decline from a profit of RMB 120,971,502.78 in the previous period[26] - The net profit for the third quarter of 2022 was -18,380,380.51 CNY, compared to a net profit of 121,021,881.50 CNY in the same period last year, indicating a significant decline[27] - The total revenue from operating activities was 556,680,888.09 CNY, down from 577,286,645.38 CNY year-over-year, reflecting a decrease of approximately 3.5%[28] - The company experienced a total comprehensive loss of -18,380,380.51 CNY for the quarter, aligning with the net loss reported[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥978,654,484.61, an increase of 0.86% from the end of the previous year[5] - Total liabilities increased to RMB 283,116,750.51 from RMB 212,535,291.07, indicating a significant rise in financial obligations[24] - The total equity attributable to shareholders decreased to RMB 695,537,734.10 from RMB 757,810,648.61, reflecting a decline in shareholder value[24] Operating Costs and Expenses - The company's operating costs increased by 44.28% to ¥391,488,946.25 due to significant promotional investments in overseas markets[11] - Operating costs surged to RMB 592,534,091.04, compared to RMB 451,708,983.89 in the prior period, reflecting increased operational expenses[26] - Research and development expenses rose to RMB 77,079,189.10, up from RMB 69,316,626.75, highlighting a focus on innovation[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,986[14] - The largest shareholder, Chen Qinfang, holds 37.00% of shares, totaling 63,270,900 shares[14] - The company plans to repurchase shares with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 35.00 per share[16] - The repurchase price has been adjusted to not exceed RMB 24.79 per share, with an estimated repurchase quantity of 201,694.2 shares at the lower limit and 403,388.4 shares at the upper limit[18] - As of September 30, 2022, the company has repurchased a total of 390,000 shares, accounting for 0.11% of the total share capital, with a total payment of RMB 7,250,795.4[19] - The company distributed cash dividends of RMB 3 per 10 shares, totaling RMB 36,640,723.5, and increased total share capital by 48,854,298 shares through capital reserve conversion[19] Government Support and Investments - The company received government subsidies amounting to ¥6,631,472.74, a 611.12% increase compared to the previous year[11] - The company plans to continue expanding its market presence and investing in new game development despite current challenges[11] - The company transferred assets related to its daily chemical business to its wholly-owned subsidiary, with a book value of RMB 181,202,454.10[20] - The company plans to acquire 100% equity of Kashgar Aoshut Network Technology Co., Ltd. for RMB 21,900 million, with a 30% advance payment already made[21] - The company is actively progressing with the acquisition project, with further details disclosed in public announcements[21] Cash Flow and Liquidity - The company's cash and cash equivalents decreased to RMB 121,681,883.77 from RMB 250,898,429.01, indicating liquidity challenges[23] - The cash inflow from investment activities was 227,103,942.61 CNY, down from 374,835,397.52 CNY year-over-year, indicating a decline in cash generated from investments[28] - The total cash outflow from investing activities was 216,512,219.29 CNY, compared to 320,561,837.02 CNY in the previous year, indicating a reduction in investment expenditures[28] - The cash flow from financing activities resulted in a net outflow of -49,724,015.09 CNY, compared to -73,667,624.02 CNY in the same period last year, showing an improvement in financing cash flow[29] - The cash and cash equivalents at the end of the period were 121,681,883.77 CNY, down from 175,823,317.82 CNY at the end of the previous year, representing a decrease of about 30.8%[29] Market and Product Development - The company did not report any new product launches or significant market expansion strategies during this quarter[30]